Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is
approved in the United States and Europe for patients with relapsed/refractory multiple …

PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …

Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in
treating relapsed or refractory multiple myeloma (MM) in both early-and late-line settings …

Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed/refractory
multiple myeloma (RRMM). This study aimed to investigate the impact of absolute …

Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …

Multiple myeloma is a disease related to the proliferation of malignant plasma cells; in most
patients, the disease is confined to the level of bone marrow. However, in a minority of …

Background/Objectives: Idecabtagene vicleucel (ide-cel), an anti-B-cell maturation chimeric
antigen receptor T-cell therapy, represents an unprecedented treatment option for …

The past decade has seen the development of immunotherapy for the treatment of multiple
myeloma (MM), beginning with monoclonal antibodies (mAbs) in the relapsed and refractory …

Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized the management of
relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is …

To synthesize the evidence on the efficacy and safety of teclistamab in treating
relapsed/refractory multiple myeloma (RRMM). A systematic search for records published …